CaMKll is a tightly regulated cardiac enzyme implicated in the development of heart failure, arrhythmias and cardiomyocyte survival. This proposal uses a unique set of genetically modified transgenic and knockout mice in which CaMKII5, the predominant CaMKII isoform in the heart, and its splice variants CaMKII6B and 5c are deleted or overexpressed so as to allow independent evaluation of their functions and effects at the nucleus, SR, and mitochondria. The proposal tests the hypothesis that the localization and molecular interactions of CaMKII create platforms which specify whether CaMKII activation effects changes in Ca handling, gene expression or mitochondrial cell death pathways. The proposed experiments study both in vivo function and in vitro cellular mechanisms.
In Aim #1 we ask whether there Is specificity in the activation of CaMKII In different subcellular compartments depending on the intervention.
Sub aims determine if exclusively expressed CaMKII6B and 6c are differentially activated, in which subcellular compartments CaMKII is activated, whether CaMKII is translocated following its activation, and whether the minor cardiac isoforms, CaMKlip and CaMKlly , alter CaMKIIS activation.
In Aim #2 we explore the consequences of subtype or compartmentalized CaMKII activity on cardiac function.
Sub aims determine whether nuclear CaMKII mediates hypertrophy in response to ET-1, whether SR localized CaMKII and its effects on RyR2 phosphorylation mediate heart failure (HF) development, and whether CaMKIISs and 5c subserve distinct and opposing functions in ischemia induced injury and HF.
Aim #3 investigates the proteins that interact with, are phosphorylated by and are transcriptionally activated in response to cardiac CaMKIISsand 6c activation using proteomics and gene arrays to explore distinct partners, phosphorylation targets and transcriptional programs.
The final Aim #4 addresses how CaMKII regulates mitochondrial cell survival.
Sub aims consider whether CaMKIISe and 5c differentially affect mitochondrial cell death pathways, if this occurs through proteins that are phosphorylated or transcriptionally regulated by CaMKII, and whether CaMKII directly associates with mitochondria to regulate mitochondrial function. The significance of this work comes from the increasing and compelling evidence that CaMKII is a novel potential therapeutic target for treatment of HF. Distinguishing the maladaptive and adaptive roles of CaMKII subtype activation at different cellular compartments and defining its targets is a means of understanding how to confer drug specificity.
Cardiac disease and development of heart failure are amongst the primary causes of death in the nation and worldwide. We have discovered that a particular molecule called CaM kinase II is regulated in response to cardiac stress and injury and is a major factor in heart failure development. Here we seek to further understand what makes this enzyme active, where in the cell it works, and which of its effects would be useful therapeutic targets.
|Hegyi, Bence; Bossuyt, Julie; Griffiths, Leigh G et al. (2018) Complex electrophysiological remodeling in postinfarction ischemic heart failure. Proc Natl Acad Sci U S A 115:E3036-E3044|
|Willeford, Andrew; Suetomi, Takeshi; Nickle, Audrey et al. (2018) CaMKII?-mediated inflammatory gene expression and inflammasome activation in cardiomyocytes initiate inflammation and induce fibrosis. JCI Insight 3:|
|Wood, Brent M; Simon, Mitchell; Galice, Samuel et al. (2018) Cardiac CaMKII activation promotes rapid translocation to its extra-dyadic targets. J Mol Cell Cardiol 125:18-28|
|Hegyi, Bence; Bossuyt, Julie; Ginsburg, Kenneth S et al. (2018) Altered Repolarization Reserve in Failing Rabbit Ventricular Myocytes: Calcium and ?-Adrenergic Effects on Delayed- and Inward-Rectifier Potassium Currents. Circ Arrhythm Electrophysiol 11:e005852|
|Yan, Jiajie; Zhao, Weiwei; Thomson, Justin K et al. (2018) Stress Signaling JNK2 Crosstalk With CaMKII Underlies Enhanced Atrial Arrhythmogenesis. Circ Res 122:821-835|
|Kanaporis, Giedrius; Blatter, Lothar A (2017) Alternans in atria: Mechanisms and clinical relevance. Medicina (Kaunas) 53:139-149|
|Yuen, Garrick K; Galice, Samuel; Bers, Donald M (2017) Subcellular localization of Na/K-ATPase isoforms in ventricular myocytes. J Mol Cell Cardiol 108:158-169|
|Gray, Charles B B; Suetomi, Takeshi; Xiang, Sunny et al. (2017) CaMKII? subtypes differentially regulate infarct formation following ex vivo myocardial ischemia/reperfusion through NF-?B and TNF-?. J Mol Cell Cardiol 103:48-55|
|Maxwell, Joshua T; Blatter, Lothar A (2017) A novel mechanism of tandem activation of ryanodine receptors by cytosolic and SR luminal Ca2+ during excitation-contraction coupling in atrial myocytes. J Physiol 595:3835-3845|
|Burel, Sophie; Coyan, Fabien C; Lorenzini, Maxime et al. (2017) C-terminal phosphorylation of NaV1.5 impairs FGF13-dependent regulation of channel inactivation. J Biol Chem 292:17431-17448|
Showing the most recent 10 out of 233 publications